Exploring the role and clinical implications of proteasome inhibition in medulloblastoma
| Autor: | Hoerig, Clay M, Plant-Fox, Ashley S, Pulley, Michelle D, Di, Kaijun, Bota, Daniela A |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pediatric
Proteasome Endopeptidase Complex Pediatric Research Initiative Clinical Sciences Oncology and Carcinogenesis Neurosciences Apoptosis medulloblastoma Brain Disorders Brain Cancer Paediatrics and Reproductive Medicine proteasome Rare Diseases 5.1 Pharmaceuticals ubiquitin Humans 2.1 Biological and endogenous factors marizomib Oncology & Carcinogenesis Development of treatments and therapeutic interventions Aetiology Cerebellar Neoplasms Proteasome Inhibitors Cancer |
| Zdroj: | Pediatric blood & cancer, vol 68, iss 10 |
| Popis: | Ubiquitin proteasome-mediated protein degradation has been implicated in posttranslational oncogenesis in medulloblastoma. Current research is evaluating the clinical implications of proteasome inhibition as a therapeutic target. In medulloblastoma cell lines, proteasome inhibitors induce apoptosis and inhibit cell proliferation via multiple pathways involving activation of caspase pathways, NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway inhibition, reduced AKT/mTOR pathway activity, and pro-apoptotic protein expression. Second-generation proteasome inhibitors demonstrate blood-brain barrier penetration while maintaining antitumor effect. This review summarizes the ubiquitin-proteasome system in the pathogenesis of medulloblastoma and the potential clinical implications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|